Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences (GENFF) is a biotechnology innovator developing gene therapies targeting age-related diseases through its pioneering SIRT6 research. This page provides investors and industry professionals with timely updates on clinical trials, regulatory milestones, and strategic partnerships shaping the future of longevity medicine.
Access comprehensive coverage of GENFF's press releases, including advancements in treatments for conditions like NASH and sarcopenia. Our curated news collection ensures you stay informed about licensing agreements, patent developments, and financial updates critical to evaluating the company's progress.
Key content categories include clinical trial results, research collaborations with leading institutions, intellectual property announcements, and analysis of therapeutic pipelines. Bookmark this page for direct access to verified information about GENFF's work in gene therapy and regenerative medicine.
Check back regularly for objective reporting on Genflow Biosciences' contributions to biotech innovation, supported by updates from peer-reviewed journals and regulatory filings. Never miss a development in this cutting-edge field of age-defying medical research.
Genflow Biosciences (LSE:GENF, OTCQB:GENFF), an emerging leader in longevity research, announced receiving €395,847, representing 50% of the Exofastrack research grant from the Government of Wallonia. This grant, a non-dilutive, non-reimbursable subsidy, will cover 80% of the expenses for a 3-year scientific program in collaboration with EXO Biologics. The program aims to develop exosome-based therapies targeting liver fibrosis (MASH) and Werner Syndrome. CEO Dr. Eric Leire expressed enthusiasm, emphasizing the potential for groundbreaking treatments in age-related disease prevention.
Genflow Biosciences, an emerging leader in longevity research, has announced its Annual General Meeting (AGM) scheduled for June 27, 2024, at 12 pm in London. The Notice of AGM and the 2024 Form of Proxy will soon be available on the company's website. Additionally, the company has published its Annual Report and Accounts for the year ending December 31, 2023, on the website.
Genflow Biosciences has announced the receipt of €381,434, which is 50% of a research grant from the Government of Wallonia in Belgium. This non-diluting and non-reimbursable grant will fund Genflow's sarcopenia research project over the next three years, conducted in partnership with Revatis SA. The project focuses on developing muscle progenitor cells (MPCs) loaded with Genflow's proprietary SIRT6 gene to prevent and treat sarcopenia. The remaining grant amount will be disbursed over the next two years based on submitted invoices. The goal is to enhance muscle regeneration and improve the quality of life for older adults affected by muscle loss.
Genflow Biosciences PLC disclosed a major holding by Jonathan Mark Swann, increasing the voting rights to 5.03% with 17,586,000 shares on May 9th, 2024. The London-based company received the notification on May 10th, 2024. The disclosure follows the standard TR-1 form for major holdings. The shareholder, Jonathan Mark Swann, is based in Rickmansworth, United Kingdom.
Genflow Biosciences Plc, a leader in longevity research, announces the restoration of its listing on the London Stock Exchange after publishing its FY23 Results. The Company's ordinary shares are set to be relisted, marking a significant milestone in its financial journey.
Genflow Biosciences Plc, an emerging leader in longevity research, announces its final results for the year ended 31 December 2023. The company focuses on developing therapeutic solutions for age-related diseases. Genflow is the first longevity biotechnology company listed in Europe.
Genflow Biosciences PLC announces a temporary suspension of listing due to delays in publishing its Annual Financial Report for the financial year ending on December 31, 2023. The delay is not related to the company's financial position. The listing of the company's ordinary shares on the Main Market of the London Stock Exchange will be temporarily suspended from May 1, 2024.
Genflow Biosciences PLC, a leader in longevity research, disclosed its total voting rights on April 30, 2024. The company's total issued share capital consists of 349,706,618 Ordinary Shares with no shares held in treasury, resulting in the same number of voting rights. Shareholders can use this figure to determine their disclosure obligations under the Financial Conduct Authority's rules.
FAQ
What is the current stock price of Genflow Biosciences (GENFF)?
What is the market cap of Genflow Biosciences (GENFF)?
